Skip to main content
SpringerLink
Log in

La rectite réfractaire

  • Chapter
Post’U FMC-HGE

  • 183 Accesses

Résumé

Au sein des maladies inflammatoires chroniques de l’intestin (MICI), l’atteinte isolée du rectum constitue une entité à part entière, tant au plan topographique que pronostique. La majorité des rectites cryptogénétiques correspond à des formes distales de rectocolite ulcéro-hémorragique (RCH), et plus rarement des formes distales de maladie de Crohn ou de colite inclassée. Près de la moitié des patients souffrants de RCH ont une atteinte limitée au rectum, dont 10 % vont répondre à la définition de la rectite réfractaire [1]. Malgré sa fréquence, la forme distale n’est que rarement individualisée au sein des études publiées sur la RCH; les informations se nichent au sein de cohortes de patients atteints de formes plus étendues (colites gauches) ou diffuses (pancolite).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Seksik P, Contou JF, Ducrotte P, Faucheron JL, de Parades V. The treatment of distal ulcerative colitis. Gastroenterol Clin Biol 2004;28:964–73.

    PubMed  Google Scholar 

  2. Marteau P, Seksik P, Beaugerie L, Bouhnik Y, Reimund JM, Gambiez L, et al. Recommendations for clinical practice for the treatment of ulcerative colitis. Gastroenterol Clin Biol 2004;28:955–60.

    PubMed  Google Scholar 

  3. Okawa K, Aoki T, Sano K, Harihara S, Kitano A, Kuroki T Ulcerative colitis with skip lesions at the mouth of the appendix: a clinical study.Am J Gastroenterol 1998;93:2405–10.

    Article  CAS  PubMed  Google Scholar 

  4. Godeberge P Management of idiopathic proctitis. Gastroenterol Clin Biol 2004;28:D70–4.

    PubMed  Google Scholar 

  5. Kojima T, Watanabe T, Hata K, Shinozaki M, Yokoyama T, Nagawa H. Cytomegalovirus infection in ulcerative colitis. Scand J Gastroenterol 2006;41:706–11.

    Article  PubMed  Google Scholar 

  6. Langmead L, Rampton DS Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:341–9.

    Article  CAS  PubMed  Google Scholar 

  7. Matsuoka K, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 2007;102:331–7.

    Article  PubMed  Google Scholar 

  8. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008:CD000011.

    Google Scholar 

  9. D’Inca R, Bertomoro P, Mazzocco K, Vettorato MG, Rumiati R, Sturniolo GC. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2008;27:166–72.

    Article  CAS  Google Scholar 

  10. Leong RW, Lawrance IC, Ching JY, Cheung CM, Fung SS, Ho JN, et al. Knowledge, quality of life, and use of complementary and alternative medicine and therapies in inflammatory bowel disease: a comparison of Chinese and Caucasian patients. Dig Dis Sci 2004;49:1672–6.

    Article  PubMed  Google Scholar 

  11. Moshkovska T, Stone M, Baker R, Mayberry J. Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis. Inflamm Bowel Dis 2008;14:763–8.

    Article  PubMed  Google Scholar 

  12. Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis-howmuch is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006;4:614–20.

    Article  PubMed  Google Scholar 

  13. Meucci G, Vecchi M, Astegiano M, Beretta L, Cesari P, Dizioli P, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol 2000;95:469–73.

    Article  CAS  PubMed  Google Scholar 

  14. Somerville KW, Langman MJ, Kane SP, MacGilchrist AJ, Watkinson G, Salmon P. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foamand prednisolone 21-phosphate enemas. Br Med J (Clin Res Ed) 1985;291:866.

    Article  CAS  Google Scholar 

  15. Ardizzone S, Doldo P, Ranzi T, Sturniolo GC, Giglio LA, Annese V, et al. Mesalazine foam (Salofalk(TM) foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalko(TM) enema. Italian Journal of Gastroenterology and Hepatology 1999;31:677–84.

    CAS  PubMed  Google Scholar 

  16. Godeberge P, Blain A, Christidis C, Mal F. Medical-surgical decisionmaking for the treatment of polypoid lesions of the colon. Gastroenterol Clin Biol 2008;32:S152–7.

    Article  CAS  PubMed  Google Scholar 

  17. Riley SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 1998;42:761–3.

    Article  CAS  PubMed  Google Scholar 

  18. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867–71.

    CAS  PubMed  Google Scholar 

  19. Allison MC, Vallance R. Prevalence of proximal faecal stasis in active ulcerative colitis. Gut 1991;32:179–82.

    Article  CAS  PubMed  Google Scholar 

  20. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40:775–81.

    Article  CAS  PubMed  Google Scholar 

  21. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549–53.

    Article  CAS  PubMed  Google Scholar 

  22. Bitton A. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis. Semin Gastrointest Dis 2001;12:263–74.

    CAS  PubMed  Google Scholar 

  23. Wright JP, Winter TA, Candy S, Marks I. Sucralfate and methylprednisolone enemas in active ulcerative colitis: A prospective, single-blind study. Digestive Diseases and Sciences 1999;44:1899–901.

    Article  CAS  PubMed  Google Scholar 

  24. Biddle WL, Miner PB, Jr. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990;99:113–8.

    CAS  PubMed  Google Scholar 

  25. Hanauer SB. Medical therapy of ulcerative colitis. Lancet 1993;342:412–7.

    Article  CAS  PubMed  Google Scholar 

  26. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000:CD000543.

    Google Scholar 

  27. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.

    Article  CAS  PubMed  Google Scholar 

  28. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250–60; quiz 520.

    Article  CAS  PubMed  Google Scholar 

  29. Afif W, Leighton JA, Hanauer SB, Loftus EV, Jr., Faubion WA, Pardi DS, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302–7.

    Article  PubMed  Google Scholar 

  30. Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28: 966–72.

    Article  CAS  PubMed  Google Scholar 

  31. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416–21.

    Article  CAS  PubMed  Google Scholar 

  32. Brunel M, Penna C, Tiret E, Balladur P, Parc R. Restorative proctocolectomy for distal ulcerative colitis. Gut 1999;45:542–5.

    Article  CAS  PubMed  Google Scholar 

  33. Patz J, Jacobsohn WZ, Gottschalk-Sabag S, Zeides S, Braverman DZ. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J Gastroenterol 1996;91:731–4.

    CAS  PubMed  Google Scholar 

  34. Guslandi M, Frego R, Viale E, Testoni PA. Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. Can J Gastroenterol 2002;16:293–6.

    PubMed  Google Scholar 

  35. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126:364–71.

    CAS  PubMed  Google Scholar 

  36. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994;330:811–5.

    Google Scholar 

  37. Winter TA, Dalton HR, Merrett MN, Campbell A, Jewell DP. Cyclosporin A retention enemas in refractory distal ulcerative colitis and ‘pouchitis’. Scand J Gastroenterol 1993;28:701–4.

    Article  CAS  PubMed  Google Scholar 

  38. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429–35.

    CAS  PubMed  Google Scholar 

  39. Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008;28:1214–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinique du Trocadéro, Paris, 10, rue Jean-Richepin, 75116, Paris

    P. Godeberge

  2. Département médico-chirurgical de pathologie digestive, Institut Mutualiste Montsouris, Université Paris V, Paris

    P. Godeberge

Authors
  1. P. Godeberge
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Michel Greff Marc Barthet Laurent Beaugerie Yoram Bouhnik Jean-Pierre Bronowicki Bruno Buecher Jacques Corallo Pierre-Adrien Dalbies Franck Devulder Philippe Ducrotte Denis Grasset Jean-Paul Jacques Jean Lapuelle Philippe Levy Olivier Nouel Patrice Pienkowski Bertrand Pujol Gilbert Tucat Pascale Rouvière

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Godeberge, P. (2010). La rectite réfractaire. In: Greff, M., et al. Post’U FMC-HGE. Springer, Paris. https://doi.org/10.1007/978-2-8178-0097-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0097-4_1

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0096-7

  • Online ISBN: 978-2-8178-0097-4

Publish with us

Policies and ethics

Search

Navigation